Pioglitazone
Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
Seung Up KimSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evogliptin Seung Up Kim | Phase 4 | BB |
Same molecule, other indications
Pioglitazone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →